# Direct oral anticoagulants are effective in preventing but not resolving radial artery occlusion: a systematic review and meta-analysis of randomized controlled trials

**Authors:** Amal A. Alsubaiei, Abdullatif A. Alfehaid, Mooza M. Alzayed, Ali Saad Artam, Osama T. Almutairi, Mohammed S. A. Alajmi, Yaqeen H. Alaraibi, Abdullah A. Alibrahim, Omar F. Alawadhi, Abdullah M. Alharran

PMC · DOI: 10.3389/fcvm.2026.1653388 · Frontiers in Cardiovascular Medicine · 2026-02-11

## TL;DR

Direct oral anticoagulants help prevent radial artery blockage after medical procedures but do not help unblock it.

## Contribution

This study is the first to systematically review and meta-analyze the role of DOACs in preventing and resolving radial artery occlusion.

## Key findings

- DOACs significantly reduced the risk of radial artery occlusion.
- DOACs did not improve resolution of existing radial artery occlusion.
- No significant differences in bleeding complications were observed between groups.

## Abstract

This systematic review, including a meta-analysis, aimed to investigate the efficacy and safety of direct oral anticoagulants (DOACs) in preventing and resolving radial artery occlusion (RAO) following transradial artery access.

We synthesized evidence from randomized controlled trials (RCTs) identified in PubMed, CENTRAL, Scopus, and Web of Science up to May 2025. Using Stata MP v. 17, we employed a fixed-effects model to report dichotomous outcomes, presenting relative risk ratio (RR) with a 95% confidence interval (CI). Trial sequential analysis (TSA) was conducted to investigate the robustness and reliability of the cumulative evidence.

Four RCTs with 970 participants were included. DOACs significantly decreased the incidence of RAO [RR: 0.49, 95% (0.31, 0.79), p < 0.001]. However, in terms of RAO resolution, there were no differences between groups [RR: 1.22, 95% CI (0.80, 1.88), p = 0.36]. Moreover, there were no differences between groups regarding the incidence of hematoma [RR: 0.56, 95% (0.12, 2.61), p = 0.46], minor bleeding [RR: 1.55, 95% (0.72, 3.32), p = 0.26], and major bleeding [RR: 2.41, 95% (0.48, 12.25), p = 0.36]. There were no incidences of arteriovenous fistula, pseudoaneurysm, or compartment syndrome throughout the trials.

DOACs significantly prevented the incidence of RAO, although TSA indicates that this finding is not yet conclusive. No significant differences were found between groups regarding RAO resolution or the incidence of hematoma, minor bleeding, or major bleeding.

https://www.crd.york.ac.uk/prospero/, identifier CRD420251063999.

## Linked entities

- **Diseases:** compartment syndrome (MONDO:0004001)

## Full-text entities

- **Diseases:** vessel occlusion (MESH:C536223), pseudoaneurysm (MESH:D017541), diabetes (MESH:D003920), edema (MESH:D004487), DM (MESH:D009223), Hematoma (MESH:D006406), hyperlipidemia (MESH:D006949), trauma to (MESH:D014947), radial artery thrombosis (MESH:D002341), artery spasm (MESH:D020301), bleeding (MESH:D006470), hypercoagulability (MESH:D019851), vascular complications (MESH:D003925), cardiovascular disease (MESH:D002318), TRA (MESH:D012078), compartment syndrome (MESH:D003161), vascular injury (MESH:D057772), thrombus (MESH:D013927), hypertension (MESH:D006973), RAO (MESH:D001157), intimal hyperplasia (MESH:D006965), arteriovenous fistula (MESH:D001164), kidney diseases (MESH:D007674), peripheral artery disease (MESH:D058729)
- **Chemicals:** enoxaparin (MESH:D017984), edoxaban (MESH:C552171), apixaban (MESH:C522181), dabigatran (MESH:D000069604), nitroglycerin (MESH:D005996), DOAC (-), heparin (MESH:D006493), NOAC (MESH:C065145), low-molecular-weight heparin (MESH:D006495), Rivaroxaban (MESH:D000069552)
- **Species:** Nicotiana tabacum (American tobacco, species) [taxon 4097], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12932602/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12932602/full.md

## References

31 references — full list in the complete paper: https://tomesphere.com/paper/PMC12932602/full.md

---
Source: https://tomesphere.com/paper/PMC12932602